Julie M. Paik

Dec 11, 2024 | jamanetwork.com | Helen Tesfaye |Julie M. Paik |Miin Roh |Phyo T. Htoo

Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes Key PointsQuestion  Is there an association between empagliflozin and the risk of nonproliferative diabetic retinopathy (NPDR) and diabetic retinopathy (DR) progression in patients with type 2 diabetes (T2D)?

May 28, 2024 | jamanetwork.com | Po-Ren Hsiao |James Cheng-Chung Wei |Julie M. Paik |Helen Tesfaye

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Nephrolithiasis in Clinical Practice SGLT2 Inhibitors and Nephrolithiasis Risk in Type 2 Diabetes Julie M. Paik, MD, ScD, MPH; Helen Tesfaye, PharmD, MSc; Gary C. Curhan, MD, ScD; Heidi Zakoul, BA; Deborah J. Wexler, MD, MSc; Elisabetta Patorno, MD, DrPH Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Nephrolithiasis in Clinical Practice—Reply Julie M.

Jan 29, 2024 | jamanetwork.com | Julie M. Paik |Helen Tesfaye |Gary Curhan |Heidi Zakoul

Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes Key PointsQuestion  What is the association between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and risk of developing nephrolithiasis in patients with type 2 diabetes?

Dec 13, 2023 | kidney-international.org | Katsiaryna Bykov |Julie M. Paik

1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA 2Diabetes Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA 3Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA 4Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts,...

Oct 25, 2023 | onlinelibrary.wiley.com | Phyo T. Htoo |Robert J Glynn |Shirley Wang |Julie M. Paik

CONFLICT OF INTEREST STATEMENT Dr. Htoo was previously an employee of Johnson & Johnson on work unrelated to the submitted work. Dr. Schneeweiss reported receiving grants from Boehringer Ingelheim and personal fees from Aetion outside the submitted work. Dr. Glynn reported receiving grants from Amarin Corporation, Kowa Pharmaceuticals America, Novartis, and Pfizer outside the submitted work.